Announcing Connect2CA the new Online Resource for Global Life Science Companies and Learn about Upcoming Events
President & CEO
CLSA – California Life Sciences Association
July 20, 2016
Welcoming New Members
Please welcome our newest CLSA members: Amaryllis, Nucleics, BioINK, Cepheus Biosciences, Inc., Igantia, Rex Animal Health, SeaSpine, SyntheX, and Veracyte, Inc.! These organizations join our 750+ membership portfolio to add significant expertise and resources to the CLSA network.
Afternoon with Thought Leaders Program
On July 28, we’re excited to be hosting our Annual Afternoon with Thought Leaders program in San Diego, with featured videoconference keynote, Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention. This program will focus on Pandemic Preparedness: The Public-Private Research and Response Infrastructure.
As current and past experience has demonstrated, effective and timely responses to emergent public health emergencies and pandemic threats – Ebola, H1N1, SARS, Zika, etc. – require the coordination and collaboration of numerous governmental public health agencies, non-profits, private industry and other important stakeholders. Our program, will serve to examine these critical partnerships, how our nation’s pandemic preparedness and response infrastructure functions, and how it can be improved, including the role of industry. Our esteemed panel following our keynote includes: Dr. David Ecker, Divisional Vice President of Abbott, Quita Highsmith, Genentech Franchise Head of Tamiflu, Dr. Rekha Murthy, Vice President of Medical Affairs at Cedars Sinai Medical Center, and moderator, Dr. Penny M. Heaton, Director of Vaccine Development and Surveillance at The Bill And Melinda Gates Foundation.
To learn more about our program, click here.
Following our Afternoon with Thought Leaders our third quarter CLSA Board Meeting will be taking place for a discussion on the current healthcare landscape and innovation in life sciences to help shape CLSA’s agenda and organizational goals as we focus on our collective mission of helping grow and foster California’s world-leading life sciences sector. These leaders and their respective organizations exemplify the depth and range of CLSA’s membership and what we stand for in advancing hope for patients and consumers in California, across our country and around the world.
California Life Sciences Association Launches New Online Resource for Global Life Science Companies
I am thrilled to announce the launch of Connect2CA, a new online resource for global life sciences companies seeking to access California’s vibrant life sciences ecosystem.
Connect2CA is a unique portal providing insight into California’s life sciences infrastructure, resources, information and access to the world’s leading innovators. The online resource arms prospective organizations, visitors, and interested parties with exclusive insight into the Golden State’s life sciences infrastructure and offerings, including identifying new ways to find relocation incentives, real estate listings, vendors, partners and talent.
Powered by CLSA, Connect2CA offers insight into a number of facets of the sector, including:
- Why California?: information on California’s life science leadership and ecosystem
- Economic engine: a quantitative look into California’s life sciences economic powerhouse
- Business incentives: insight into local and state incentives
- Real estate: member-only access to commercial real estate listings, lab spaces and incubator opportunities
- Industry networking: a portal connecting vendors with contract research organizations (CRO) & contract manufacturing organizations (CMO) to find new leads and RFPs
- Career center: access to local talent at reduced rates, and entrance to a vast resume bank
- Directory: directory of more than 750 CLSA members across all facets of California’s life sciences ecosystem
Interested parties can register by visiting www.califesciences.org and creating an account.
SB 1010 and Value of Innovation Initiative Update
On June 29, Senate Bill (SB) 1010 passed by the California Assembly Health Committee, however CLSA remains confident that once all the facts are known about the bill, lawmakers will agree SB 1010 is the wrong prescription for California. SB 1010 prioritizes paperwork, red tape and bureaucracy over research, and instead of improving patient access and affordability, places patients in California at risk.
As innovators in the life sciences sector dedicated to the development of treatments and cures for patients across multiple disease states and levels, we are disappointed by the action of the California Assembly Health Committee to approve SB 1010. While rising healthcare costs are a concern for many Californians, SB 1010 could actually make issues of affordability worse for the most vulnerable Californians.
Click here to view more on what CLSA is doing on SB 1010 and learn more about other advocacy efforts.
President & CEO
California Life Sciences Association
PS – Have newsworthy items to submit for consideration for our monthly CLSA Bulletin? Feel free to send those tips to Bianca Leveriza, CLSA’s Associate, Marketing & Events (BLeveriza@CALifeSciences.org).